CN115819542B - Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide - Google Patents
Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide Download PDFInfo
- Publication number
- CN115819542B CN115819542B CN202211045917.4A CN202211045917A CN115819542B CN 115819542 B CN115819542 B CN 115819542B CN 202211045917 A CN202211045917 A CN 202211045917A CN 115819542 B CN115819542 B CN 115819542B
- Authority
- CN
- China
- Prior art keywords
- peptide
- cell
- epitope
- screening
- dominant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 155
- 239000000427 antigen Substances 0.000 title claims abstract description 15
- 108091007433 antigens Proteins 0.000 title claims abstract description 15
- 102000036639 antigens Human genes 0.000 title claims abstract description 15
- 238000012216 screening Methods 0.000 title abstract description 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 41
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 33
- 238000011161 development Methods 0.000 abstract description 28
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 27
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 25
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 17
- 210000002966 serum Anatomy 0.000 abstract description 16
- 206010014096 Echinococciasis Diseases 0.000 abstract description 13
- 208000009366 Echinococcosis Diseases 0.000 abstract description 13
- 241001494479 Pecora Species 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 7
- 229940023041 peptide vaccine Drugs 0.000 abstract description 5
- 230000007969 cellular immunity Effects 0.000 abstract description 2
- 238000005406 washing Methods 0.000 description 104
- 239000000243 solution Substances 0.000 description 74
- 239000007788 liquid Substances 0.000 description 54
- 238000002965 ELISA Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 230000002745 absorbent Effects 0.000 description 24
- 239000002250 absorbent Substances 0.000 description 24
- 238000010009 beating Methods 0.000 description 24
- 238000007789 sealing Methods 0.000 description 22
- 102100037850 Interferon gamma Human genes 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 19
- 238000000576 coating method Methods 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000007865 diluting Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 238000012258 culturing Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000020183 skimmed milk Nutrition 0.000 description 8
- 238000002649 immunization Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 101800004192 Peptide P1 Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 101001054317 Bos taurus Interferon gamma Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The application discloses screening of a dominant epitope peptide of echinococcosis granulosa recombinant antigen P29, which relates to the technical field of bioengineering and comprises the following steps of: s1, designing epitope peptide; s2, screening B cell epitope mixed peptide; s3, B cell epitope single peptide screening; s4, optimally screening B cell dominant epitope peptides; s5, screening T cell epitope mixed peptide; s6, screening T cell epitope monopeptides; s7, application of B cell dominant epitope peptide; s8, application of T cell dominant epitope peptide. Three B cell dominant epitope peptides are screened out: p1, P2 and P3 can recognize IgE, igG1 and IgG2 antibodies in immune sheep serum, can recognize IgG, igM, igG antibodies in P29 immune mouse serum in vitro, and have good antibody recognition effect; two T cell dominant epitope peptides were screened: ID18 and ID28 can stimulate immune sheep PBMC to produce cytokine IFN-gamma in vitro, and have better induced cell immunity potential. Lays a foundation for the development of the P29 multi-epitope peptide vaccine of echinococcosis.
Description
Technical Field
The application belongs to the technical field of bioengineering, and particularly relates to screening and application of a echinococci granulosa recombinant antigen P29 dominant epitope peptide.
Background
Echinococcosis granulosa, also known as echinococcosis, is a common parasitic disease shared by humans and animals, caused by the larvae of echinococcosis residing in animals (including humans). Echinococcosis granulosa presents a global distribution characteristic, is widely popular in eastern Europe, eastern africa, middle east and Asia middle parts and other areas, and is more obvious in developed areas of animal husbandry. China is one of the most serious areas of the global echinococcosis, and is more widely distributed in the areas with developed western animal husbandry. Echinococcosis not only seriously harms the health of people, but also has serious adverse effects on the development of animal husbandry, and causes huge expenses and economic losses in medical treatment and animal husbandry. Generally, the control of echinococcosis includes two links, prevention and clinical treatment. The prevention and treatment of infectious diseases by means of immunization have a longer history, and the effect and effect of immunoprophylaxis are also more prominent, which shows incomparable advantages of other prevention and treatment means. Along with the rapid development and cross fusion of multiple subjects such as molecular biology, cell biology, immunology and the like, a great deal of research work is done by numerous scientific researchers in the development of echinococcosis vaccines from the development of traditional vaccines and genetic engineering vaccines to the research of nucleic acid vaccines, polypeptide vaccines, multivalent vaccines and the like, and a certain research result is obtained.
The traditional protective antigen of the antiparasitic vaccine mostly adopts whole protein, and the components of the whole protein are relatively complex, and the whole protein not only contains effective epitopes which exert immune protection effect, namely 'dominant epitopes', but also contains ineffective epitopes, even epitopes with immune inhibition effect. The polypeptide vaccine is designed manually and synthesized according to the amino acid sequence of a certain section of antigen epitope in known or predicted echinococci effective protective antigen. The epitope peptide vaccine has a plurality of advantages over the traditional vaccine, such as being capable of selectively improving effective response, reducing side effects of the vaccine after removing irrelevant epitopes, increasing the width of immune response of the combined multi-epitope peptide vaccine, and the like. Dominant epitope screening is a precondition for developing epitope vaccine, and is optimized in the epitope layer to antigen screening, so that more effective immune response can be induced, and the immune specificity and safety are ensured. P29 can effectively induce continuous humoral immunity and cellular immune response of sheep, and is a better echinococcosis vaccine candidate molecule. The subject group has developed the research of P29 epitope peptide vaccine in a mouse animal model, and the determined antigen dominant epitope induces the mouse to generate better immune response, but the subject group lacks related data in large experimental animals such as sheep and the like.
Disclosure of Invention
The application aims at solving the existing problems and provides screening and application of a dominant epitope peptide of an echinococcosis granulosa recombinant antigen P29.
The application is realized by the following technical scheme:
screening of echinococci granulosa recombinant antigen P29 dominant epitope peptide, comprising the following steps:
s1, epitope peptide design:
according to the design principle of the overlapping peptide, designing a single peptide with the length of 15 amino acids, walking by 5 amino acids and overlapping by 10 amino acids, designing 45 overlapping single peptides in total, and covering 238 amino acids of rEg.P29, wherein the amino acid sequence is SEQ ID NO.1;
s2, screening B cell epitope mixed peptide:
selecting plasma at 6 weeks of the highest time point of the IgG antibody expression level, namely 2 weeks after the second immunization, and primarily screening the mixed peptide corresponding to the single peptide, wherein the method specifically comprises the following steps:
s201, coating mixed peptide rEg.P29: diluting (carbonate buffer, pH 9.6) each mixed peptide with coating buffer, wherein the final concentration is 5 μg/ml, adding 100 μl of peptide or antigen coating solution into each well of the ELISA plate, and incubating at 4deg.C overnight in a refrigerator;
s202, sealing: the next day, taking out the ELISA plate from the refrigerator, discarding Kong Nabao, washing the plate 5 times with 1 XPBST washing solution (PBS+0.05% Tween-20), 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper, adding 200 μl of 5% skimmed milk powder (1 XPBST dissolved) sealing solution into each hole of the ELISA plate, and incubating at 37deg.C for 2h;
s203, incubating primary antibody: discarding the sealing liquid, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, removing the washing liquid, and forcibly beating the residual washing liquid on the absorbent paper; diluting serum to 1:1000 concentration with blocking solution, adding 100 μl of diluted plasma into each well, adding 100 μl of 5% skimmed milk powder blocking solution into blank control well, and incubating at 37deg.C for 1 hr;
s204, incubating a secondary antibody: discarding the primary antibody solution after incubation, washing the plate with 1 XPBST washing solution for 5 times for 2 min/time, removing the washing solution, forcibly beating the residual washing solution on absorbent paper, diluting a rabit anti-shaep IgG-HRP antibody by 1:8000, adding 100 μl of diluted secondary antibody into each well, and incubating at 37deg.C for 1h;
s205, developing: discarding the secondary antibody after incubation, washing the plate with 1 XPBST washing liquid for 7 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, mixing TMB developing solution A with solution B in equal volume, adding 100 μl TMB developing solution into each hole, and carrying out light-shielding reaction for 10-15min, wherein the degree of color development is observed;
s206, terminating the color development: after color development to the expected depth, 50 μl of ELISA stop solution was added to each well to stop the reaction;
s207, reading data: detecting OD values of all holes in an enzyme-labeled instrument at a wavelength of 450nm within 30min after termination, and analyzing and screening out dominant mixed peptides according to the results;
s3, B cell epitope single peptide screening:
selecting plasma at week 6 of the highest time point of the IgG antibody expression level, namely, 2 weeks after the second immunization, and further screening the single peptide corresponding to the screened dominant epitope mixed peptide, wherein the process is the same as the screening of the mixed peptide, namely, the steps S201-S207;
s4, optimizing and screening B cell dominant epitope peptides:
selecting serum of the highest time point of the IgG antibody expression level, further optimizing synthesis such as tandem connection and the like according to the position and the amino acid composition of the screened dominant epitope peptide, and further screening epitope peptide with better effect than the dominant epitope peptide; the coated peptide is a newly synthesized peptide, rEg.P29 is used as a control for coating; other processes are the same as above, namely, the steps S201-S207 are performed, and more optimal epitope peptides are optimally screened;
s5, screening T cell epitope mixed peptide:
detecting IFN-gamma content in the culture supernatant after stimulating the PBMC by ELISA;
s501, PBMC stimulation culture: the isolated PBMC were adjusted to cell concentrations of 2X 10 6 After taking out the empty culture medium control group, adding the rest cells into anti-CD28 according to 1 mug/ml, uniformly mixing, and then dividing into 1.5ml EP pipes, and 700 mug/hole; stimulation grouping: (1) medium group: blank medium; (2) mixed peptide group: 10 μg/ml peptide+1 μg/ml anti-CD28; (3) eg.p29 group: 10 mug/ml rEg.P29+1 mug/ml anti-CD28, adding overlapping peptide, rEg.P29 and other stimulant, each group having 3 multiple holes, each hole200 μl of the cell suspension with the addition of the stimulant; 37 ℃,5% CO 2 Culturing in an incubator for 96 hours, collecting cell supernatant, and detecting cytokine expression in the culture supernatant by ELISA (Bovine IFN-. Gamma.ELISA by Mebtech Co., ltd.) BASIC kit detection);
s502, antibody coating: mAb MT17.1 of Bovine IFN-gamma was diluted to 2. Mu.g/ml with PBS, 100. Mu.l of antibody coating solution was added to each well of a 96-well ELISA plate, and incubated overnight at 4℃in a refrigerator;
s503, sealing: the next day, the ELISA plate was removed from the refrigerator, kong Nabao was discarded, 200 μl of 0.1% BSA (1 XPBST-solubilized) blocking solution was added to each well and incubated for 1h at room temperature;
s504, sample adding: removing sealing liquid after sealing, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, and forcibly beating the residual washing liquid on absorbent paper after the washing liquid is thrown off; adding 100 mu l of diluted culture supernatant and standard substances into each well, and only adding 100 mu l of sample diluent into a blank control well for incubation for 2 hours at room temperature;
s505, adding detection antibody: discarding the sample, washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper; mAb MT307-biotin is diluted to 0.25 mug/ml with PBS, 100 mug/well is added in the ELISA plate and incubated for 1h at room temperature;
s506, adding strepavidin-HRP: washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper; the strepitavidin-HRP is diluted to 1:1000, 100 μl is added to each well, and the mixture is incubated for 1h at room temperature;
s507, color development: washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper, adding 100 μl TMB color development solution into each hole, and reacting for 15min in dark place;
s508, terminating the color development: after the end of the development, 100. Mu.l of 0.2. 0.2M H were added to each well 2 SO 4 Terminating the reaction;
s509, reading data: detecting OD values of all holes in an enzyme-labeled instrument at a wavelength of 450nm within 15min after termination, drawing a standard curve, analyzing IFN-gamma content in culture supernatants of all groups, and screening out T cell epitope mixed peptides;
s6, T cell epitope single peptide screening:
and (3) after the PBMC is stimulated by the monopeptides rEg.P29 corresponding to the screened dominant epitope mixed peptide, detecting IFN-gamma content in the culture supernatant, and screening out dominant monopeptides in the same process, namely, in the steps S501-S509.
Further, the application S7 of the B cell dominant epitope peptide and the application S8 of the T cell dominant epitope peptide are also included.
Further, the application of the B cell dominant epitope peptide is that the B cell dominant epitope peptide can be identified and combined with a specific antibody in immune plasma, and the B cell dominant epitope peptide P1 screened out by coating an ELISA plate with rEg.P29 and utilizing the blood plasma of week 6 after immunization is detected: rEg.P29 71-90 、P2：rEg.P29 151-175 、P3：rEg.P29 211--235 Recognition effect on IgM, igA, igE, igG and IgG2 antibodies;
s701, peptide re.p29 coating: diluting each mixed peptide rEg.P29 with coating buffer (carbonate buffer, pH 9.6) to a final concentration of 5 μg/ml, adding 100 μl of peptide or antigen coating solution to each well of the ELISA plate, and incubating at 4deg.C overnight in a refrigerator;
s702, sealing: the next day, taking out the ELISA plate from the refrigerator, discarding Kong Nabao, washing the plate 5 times with 1 XPBST washing solution (PBS+0.05% Tween-20), 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper, adding 200 μl of 5% skimmed milk powder (1 XPBST dissolved) sealing solution into each hole of the ELISA plate, and incubating at 37deg.C for 2h;
s703, incubating primary antibody: discarding the sealing liquid, washing the plate with 1 XPBST washing liquid for 5 times, 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, diluting serum with the sealing liquid to a concentration of 1:100/1:1000, adding 100 μl of diluted plasma into each well, adding 100 μl of 5% skimmed milk powder sealing liquid into blank control wells, and incubating at 37deg.C for 1 hr;
s704, incubating a secondary antibody: discarding the primary antibody solution after the incubation is finished, washing the plate with 1 XPBST washing liquid for 5 times for 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, diluting IgM, igA, igE, igG and IgG2 antibodies, adding 100 mu l of diluted secondary antibody into each hole, and incubating for 1h at 37 ℃;
s705, color development: discarding the secondary antibody after incubation, washing the plate with 1 XPBST washing liquid for 7 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, mixing TMB developing solution A with solution B in equal volume, adding 100 μl TMB developing solution into each hole, and carrying out light-shielding reaction for 10-15min, wherein the degree of color development is observed;
s706, terminating the color development: after color development to the expected depth, 50 μl of ELISA stop solution was added to each well to stop the reaction;
s707, reading data: the OD value of each well was measured at a wavelength of 450nm in an ELISA reader within 30min after termination.
Further, the application of the T cell dominant epitope peptide is that the screened T cell dominant epitope peptide can stimulate PBMC to produce cytokine IFN-gamma in vitro;
s801, PBMC stimulation culture: removing desired cells, and adjusting cell concentration to 1×10 6 cells/ml, 1. Mu.g/ml anti-CD28 and corresponding stimulant were added at 37℃with 5% CO 2 Culturing in an incubator for 24h, adding BFA with concentration of 10 mug/ml 6h before culturing, collecting PBMC after culturing, and detecting cytokine IFN-gamma and expression; stimulation grouping: (1) medium group: blank medium; (2) single peptide group: 10 μg/ml dominant single peptide+1 μg/ml anti-CD28;
s802, cell collection: after the cultivation, PBMC were collected in a 5ml flow tube and centrifuged at 1800rpm at 4℃for 8min;
s803, cleaning: after the supernatant is discarded, 2-4 ml/tube of Buffer2 solution is added, and the mixture is centrifuged at 1800rpm and 4 ℃ for 8min and washed twice;
s804, surface dyeing: removing supernatant, dipping a tube orifice on paper, determining the number of staining tubes according to experimental requirements, resuspending cells with Buffer2 according to 100 μl/tube, adding surface antibody anti-sleep CD4/CD8, and incubating at 4deg.C in dark for 30min;
s805, washing: directly adding 2-4 ml/tube of Buffer2 solution, centrifuging at 1800rpm and 4deg.C for 8min;
s806, fixing; washing, removing supernatant, gently swirling cells, adding 4% paraformaldehyde 500-800 μl/tube, and incubating at room temperature in dark place for 8-10min (the gun head can be sheared off when sucking paraformaldehyde for sucking);
s807, washing: adding Buffer3 solution 2-4 ml/tube, centrifuging at 1800rpm and 4deg.C for 8minn (rise 7 and fall 4);
s808, rupture of membranes: removing the supernatant, slightly swirling, adding 2-4 ml/tube of Buffer3 solution, and breaking membrane at 4 ℃ overnight;
s809, intracellular staining: centrifuging at 2200rpm at 4deg.C for 8minn (lifting 7 and lowering 4) to collect cells, removing supernatant, soaking a tube orifice on paper, gently swirling cell precipitation, resuspending cells to about 100 μl/tube with Buffer3 solution, respectively adding antibody IFN-gamma, gently swirling, and incubating at 4deg.C in dark for 30min;
s8010, washing: adding Buffer2 solution 2-4 ml/tube, centrifuging at 2200rpm and 4deg.C for 8minn (rise 7 and fall 4);
s8011, on-machine detection: after removing the supernatant, gently vortexing, resuspending the cells to 300 μl/tube and performing on-machine detection to analyze CD4/CD8 + IFN-gamma expression in T cells, the dominant peptide was determined to stimulate PBMC to produce IFN-gamma.
Compared with the prior art, the application has the following advantages:
three B cell dominant epitope peptides are screened out: p1 (rEg.P29) 71-90 )、P2(rEg.P29 151-175 )、P3(rEg.P29 211-235 ) The antibody can recognize IgE, igG1 and IgG2 antibodies in immune sheep serum, can recognize IgG, igM, igG1 antibodies in P29 immune mouse serum in vitro, and has better and wider antibody recognition effects; two T cell dominant epitope peptides were screened: ID18 (rEg.P29) 86-100 ) With ID28 (rEg.P29) 136-150 ) They can stimulate immune sheep PBMC in vitro to produce cytokine IFN-gamma, and have better induced cell immunity potential. The method lays a foundation for the development of the P29 multi-epitope peptide vaccine of echinococcosis.
Drawings
FIG. 1 is a schematic representation of an overlapping peptide design strategy;
FIG. 2 shows the strategy for optimally designing and synthesizing B cell epitope peptides;
FIG. 3 is a B cell dominant epitope mixed peptide screen;
FIG. 4 is a B cell dominant epitope single peptide screen;
FIG. 5 is a B cell epitope peptide optimization screen;
FIG. 6 shows B cell epitope dominant peptide IgG titer assay;
FIG. 7 is a T cell epitope mixed peptide screen;
FIG. 8 is a T cell epitope single peptide screen;
FIG. 9 shows B cell epitope dominant peptide serum antibody detection;
FIG. 10 shows B cell epitope dominant peptide mouse plasma antibody detection;
FIG. 11 is a schematic representation of T cell epitope dominant single peptide stimulation of CD4/CD8 + IFN-gamma production by T cells.
Detailed Description
Screening of echinococci granulosa recombinant antigen P29 dominant epitope peptide, comprising the following steps:
s1, epitope peptide design:
according to the design principle of the overlapping peptide, the length of the designed single peptide is 15 amino acids, the step is 5 amino acids, the overlapping part is 10 amino acids, 45 overlapping single peptides are designed in total, the information of the overlapping peptides is shown in the following table 1, 238 amino acids of rEg.P29 are covered, the amino acid sequence of the overlapping peptides is SEQ ID NO.1, and the design strategy of the overlapping peptides is shown in figure 1;
TABLE 1 overlapping peptide information
S2, screening B cell epitope mixed peptide:
selecting plasma at 6 weeks of the highest time point of the IgG antibody expression level, namely 2 weeks after the second immunization, and primarily screening the mixed peptide corresponding to the single peptide, wherein the method specifically comprises the following steps:
s201, coating mixed peptide rEg.P29: diluting each mixed peptide with coating buffer solution to a final concentration of 5 mug/ml, adding 100 mug of peptide or antigen coating solution into each hole of an ELISA plate, and incubating at 4 ℃ overnight in a refrigerator;
s202, sealing: the next day, taking out the ELISA plate from the refrigerator, discarding Kong Nabao, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on the absorbent paper, adding 200 μl of 5% skimmed milk powder sealing liquid into each hole of the ELISA plate, and incubating at 37deg.C for 2h;
s203, incubating primary antibody: discarding the sealing liquid, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, removing the washing liquid, and forcibly beating the residual washing liquid on the absorbent paper; diluting serum to 1:1000 concentration with blocking solution, adding 100 μl of diluted plasma into each well, adding 100 μl of 5% skimmed milk powder blocking solution into blank control well, and incubating at 37deg.C for 1 hr;
s204, incubating a secondary antibody: discarding the primary antibody solution after incubation, washing the plate with 1 XPBST washing solution for 5 times for 2 min/time, removing the washing solution, forcibly beating the residual washing solution on absorbent paper, diluting a rabit anti-shaep IgG-HRP antibody by 1:8000, adding 100 μl of diluted secondary antibody into each well, and incubating at 37deg.C for 1h;
s205, developing: discarding the secondary antibody after incubation, washing the plate with 1 XPBST washing liquid for 7 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, mixing TMB developing solution A with solution B in equal volume, adding 100 μl TMB developing solution into each hole, and carrying out light-shielding reaction for 10-15min, wherein the degree of color development is observed;
s206, terminating the color development: after color development to the expected depth, 50 μl of ELISA stop solution was added to each well to stop the reaction;
s207, reading data: detecting OD values of all holes in an enzyme-labeled instrument at a wavelength of 450nm within 30min after termination, and analyzing and screening out dominant mixed peptides according to the results;
screening 15 mixed peptides of 3 adjacent single peptides by sheep IgG antibody, and identifying 5 epitope mixed peptides, namely ID13-15, ID16-18, ID31-33, ID34-36 and ID43-45 by immune serum, wherein the reactions of ID13-15 and ID16-18 are higher, and the reaction is significantly different from other mixed peptides (shown in figure 3). Each of the mixed peptides selected contained 3 single peptides, ID13, ID14, ID15, ID16, ID17, ID18, ID31, ID32, ID33, ID34, ID35, ID36, ID43, ID44, ID45, and 15 single peptides were further selected to determine the dominant epitope peptide.
FIG. 3A is a histogram of mixed peptide screening; B. mixed peptide screening thermodynamic diagrams; * P <0.0001.
S3, B cell epitope single peptide screening:
selecting plasma at week 6 of the highest time point of the IgG antibody expression level, namely, 2 weeks after the second immunization, and further screening the single peptide corresponding to the screened dominant epitope mixed peptide, wherein the process is the same as the screening of the mixed peptide, namely, the steps S201-S207;
the 15 single peptides corresponding to the preliminarily screened epitope mixed peptide are screened by using sheep IgG antibody, 8 epitope single peptides, namely ID15, ID16, ID31, ID32, ID33, ID43, ID44 and ID45 (shown in figure 4), which correspond to the 71-85AA, 76-90AA, 151-165AA, 156-170AA, 161-175AA, 211-225AA, 216-230AA and 221-235AA regions of the P29 protein respectively, are preliminarily considered to be potential linear B cell epitopes. It was found that 8 epitope peptides were located in three regions of the protein, ID15, ID16 in the 71-90AA region, ID31, ID32, ID33 in the 151-175AA region, ID43, ID44, ID45 in the 211-235AA region, and that each of these three regions was better than the single region, and the application was further validated in tandem.
In fig. 4: A. single screening of a histogram; B. single peptide screening thermodynamic diagrams; * Represents P <0.05; * Represents P <0.01; * Represents P <0.001; * P <0.0001.
S4, optimizing and screening B cell dominant epitope peptides:
selecting serum of the highest time point of the IgG antibody expression level, further optimizing synthesis such as tandem connection and the like according to the position and the amino acid composition of the screened dominant epitope peptide, and further screening epitope peptide with better effect than the dominant epitope peptide; the coated peptide is a newly synthesized peptide, rEg.P29 is used as a control for coating; other processes are the same as above, namely, the steps S201-S207 are performed, and more optimal epitope peptides are optimally screened;
three regions for the 8 epitope peptides: the 71-90AA region, the 151-175AA region and the 211-235AA region are respectively synthesized into monopeptides, the monopeptides are synthesized after the three regions are connected in series, and GSGSGS series sequence is added in the middle. A total of 6 new mono-peptides (P1-P6) were synthesized as shown in FIG. 2. Screening is carried out by using sheep IgG antibodies, immune serum recognition shows that the recognition effect of P1 (71-90 AA), P2 (151-175 AA) and P3 (211-235 AA) is obviously better than that of the corresponding monopeptides in each region, and the effect of P3 is highest, and the three monopeptides are considered to be potential linear B cell dominant epitopes. After P1, P2 and P3 are connected in series, the number of peptide amino acids is obviously increased after the series connection, and the serum recognition effect is obviously increased compared with that before the series connection, but the three peptides are not different from each other, as shown in fig. 5.
In fig. 5: * P <0.0001.
S401, B cell epitope dominant peptide IgG titer detection:
ELISA detection results show that the IgG titer corresponding to each epitope peptide gradually decreases with increasing dilution ratio by carrying out 1000, 4000, 16000, 64000 and 256000 times dilution on the plasma of the immune group, the IgG of the three monopeptides P1, P2 and P3 gradually decreases rapidly, and the titer of the three longer monopeptides P4, P5 and P6 gradually decreases, and the three antibodies have no difference (figure 6).
S5, screening T cell epitope mixed peptide:
detecting IFN-gamma content in the culture supernatant after stimulating the PBMC by ELISA;
s501, PBMC stimulation culture: the isolated PBMC were adjusted to cell concentrations of 2X 10 6 After taking out the empty culture medium control group, adding the rest cells into anti-CD28 according to 1 mug/ml, uniformly mixing, and then dividing into 1.5ml EP pipes, and 700 mug/hole; stimulation grouping: (1) medium group: blank medium; (2) mixed peptide group: 10 μg/ml peptide+1 μg/ml anti-CD28; (3) eg.p29 group: 10 mug/ml rEg.P29+1 mug/ml anti-CD28, respectively adding the overlapping peptide, rEg.P29 and other stimulators, each group is provided with 3 compound holes, and 200 mug of cell suspension added with the stimulators is added into each hole; 37 ℃,5% CO 2 Culturing in incubator for 96 hr, collecting cell supernatant, and detecting by ELISACulturing the expression of cytokines in the supernatant;
s502, antibody coating: mAb MT17.1 of Bovine IFN-gamma was diluted to 2. Mu.g/ml with PBS, 100. Mu.l of antibody coating solution was added to each well of a 96-well ELISA plate, and incubated overnight at 4℃in a refrigerator;
s503, sealing: the next day, the ELISA plate was removed from the refrigerator, kong Nabao was discarded, 200 μl of 0.1% BSA blocking solution was added to each well, and incubated for 1h at room temperature;
s504, sample adding: removing sealing liquid after sealing, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, and forcibly beating the residual washing liquid on absorbent paper after the washing liquid is thrown off; adding 100 mu l of diluted culture supernatant and standard substances into each well, and only adding 100 mu l of sample diluent into a blank control well for incubation for 2 hours at room temperature;
s505, adding detection antibody: discarding the sample, washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper; mAb MT307-biotin is diluted to 0.25 mug/ml with PBS, 100 mug/well is added in the ELISA plate and incubated for 1h at room temperature;
s506, adding strepavidin-HRP: washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper; the strepitavidin-HRP is diluted to 1:1000, 100 μl is added to each well, and the mixture is incubated for 1h at room temperature;
s507, color development: washing the plate with 1 XPBST washing solution for 5 times and 2 min/time, removing the washing solution, and forcibly beating the residual washing solution on absorbent paper, adding 100 μl TMB color development solution into each hole, and reacting for 15min in dark place;
s508, terminating the color development: after the end of the development, 100. Mu.l of 0.2M H2SO4 was added to each well to terminate the reaction;
s509, reading data: detecting OD values of all holes in an enzyme-labeled instrument at a wavelength of 450nm within 15min after termination, drawing a standard curve, analyzing IFN-gamma content in culture supernatants of all groups, and screening out T cell epitope mixed peptides;
the method comprises the steps of respectively stimulating PBMC of an 8 th week immune group by 15 mixed peptides of 3 adjacent single peptides, detecting IFN-gamma content in culture supernatant by ELISA, screening each mixed peptide, primarily screening 5 effective mixed peptides, namely ID1-3, ID7-9, ID10-12, ID16-18 and ID28-30 (shown in figure 7), wherein the corresponding single peptides are ID1, ID2, ID3, ID7, ID8, ID9, ID10, ID11, ID12, ID16, ID17, ID18, ID28, ID29 and ID30, and further screening 15 single peptides.
In fig. 7: A. screening a histogram of the mixed peptide; B. mixed peptide screening thermodynamic diagrams; the dashed line represents the threshold (normalized to mean +2SD of Medium stimulation); * Represents P <0.05; * Represents P <0.01; * Represents P <0.001; * P <0.0001.
S6, T cell epitope single peptide screening:
after stimulating PBMC with the single peptide rEg.P29 corresponding to the screened dominant epitope mixed peptide, detecting IFN-gamma content in the culture supernatant, and screening out dominant single peptide in the same process as that in the step S501-S509;
the PBMC were stimulated with 15 peptides corresponding to the initially screened mixed peptides, respectively, and 2T cell dominant single peptides were further screened, respectively ID18 (rEg.P29 86-100 )、ID28(rEg.P29 136-150 ) Among them, the ID18 is effective as shown in fig. 8.
In fig. 8: A. single peptide screening histogram; B. single peptide screening thermodynamic diagrams; * Represents P <0.05; * P <0.0001.
S7, application of B cell dominant epitope peptide:
the B cell dominant epitope peptide can be combined with specific antibody recognition in immune plasma, and is coated with an ELISA plate by rEg.P29, and the screened B cell dominant epitope peptide P1 is detected by using the blood plasma of week 6 after immunization: rEg.P29 71-90 、P2：rEg.P29 151-175 、P3：rEg.P29 211--235 Recognition effect on IgM, igA, igE, igG and IgG2 antibodies;
s701, peptide re.p29 coating: diluting each mixed peptide rEg.P29 with coating buffer solution, wherein the final concentration is 5 mug/ml, adding 100 mug of peptide or antigen coating solution into each hole of an ELISA plate, and incubating at 4 ℃ overnight in a refrigerator;
s702, sealing: the next day, taking out the ELISA plate from the refrigerator, discarding Kong Nabao, washing the plate with 1 XPBST washing liquid for 5 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on the absorbent paper, adding 200 μl of 5% skimmed milk powder sealing liquid into each hole of the ELISA plate, and incubating at 37deg.C for 2h;
s703, incubating primary antibody: discarding the sealing liquid, washing the plate with 1 XPBST washing liquid for 5 times, 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, diluting serum with the sealing liquid to a concentration of 1:100/1:1000, adding 100 μl of diluted plasma into each well, adding 100 μl of 5% skimmed milk powder sealing liquid into blank control wells, and incubating at 37deg.C for 1 hr;
s704, incubating a secondary antibody: discarding the primary antibody solution after the incubation is finished, washing the plate with 1 XPBST washing liquid for 5 times for 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, diluting IgM, igA, igE, igG and IgG2 antibodies, adding 100 mu l of diluted secondary antibody into each hole, and incubating for 1h at 37 ℃;
s705, color development: discarding the secondary antibody after incubation, washing the plate with 1 XPBST washing liquid for 7 times and 2 min/time, removing the washing liquid, forcibly beating the residual washing liquid on absorbent paper, mixing TMB developing solution A with solution B in equal volume, adding 100 μl TMB developing solution into each hole, and carrying out light-shielding reaction for 10-15min, wherein the degree of color development is observed;
s706, terminating the color development: after color development to the expected depth, 50 μl of ELISA stop solution was added to each well to stop the reaction;
s707, reading data: the OD value of each well was measured at a wavelength of 450nm in an ELISA reader within 30min after termination.
(1) Detection of the selected B cell dominant epitope peptide P1 (rEg.P29) 71-90 )、P2(rEg.P29 151-175 )、P3(rEg.P29 211-235 ) Recognition effect on IgM, igA, igE, igG and IgG2 antibodies in sheep serum. The B cell dominant epitope peptide can be combined with specific antibody recognition in immune plasma. The results showed that they were unable to recognize IgM and IgA antibodies, P1, P2, P3 could recognize IgE, igG1 and IgG2 antibodies, P4, P5, P6 antibodies were higher than P1, P2, P3, with the highest level of the three antibodies of P5 as shown in fig. 9.
In fig. 9: igm antibody; igA antibody; ige antibodies; igg1 antibody; igG2 antibody; ns indicates no significant difference; * Represents P <0.01; * Represents P <0.001; * P <0.0001.
(2) Detection of the selected B cell dominant epitope peptide P1 (rEg.P29) 71-90 )、P2(rEg.P29 151-175 )、P3(rEg.P29 211-235 ) The results of the detection of the B cell epitope dominant peptide mouse plasma antibodies in the P29 immunized mouse serum for the recognition effects of IgG, igM, igA, igE, igG, igG2a, igG2B, igG2c, and IgG3 antibodies are shown in fig. 10.
In fig. 10: ns indicates no significant difference; * Represents P <0.01; * Represents P <0.001; * P <0.0001.
S8, application of T cell dominant epitope peptide:
the screened T cell dominant epitope peptide can stimulate PBMC to produce cell factor IFN-gamma in vitro;
s801, PBMC stimulation culture: taking out the required cells, adjusting the cell concentration to 1X 106cells/ml, adding 1 mug/ml anti-CD28, adding a corresponding stimulator, culturing for 24 hours in a 5% CO2 incubator at 37 ℃, adding 10 mug/ml BFA 6 hours before culturing, collecting PBMC after culturing, and detecting the cytokine IFN-gamma expression; stimulation grouping: (1) medium group: blank medium; (2) single peptide group: 10 μg/ml dominant single peptide+1 μg/ml anti-CD28;
s802, cell collection: after the cultivation, PBMC were collected in a 5ml flow tube and centrifuged at 1800rpm at 4℃for 8min;
s803, cleaning: after the supernatant is discarded, 2-4 ml/tube of Buffer2 solution is added, and the mixture is centrifuged at 1800rpm and 4 ℃ for 8min and washed twice;
s804, surface dyeing: removing supernatant, dipping a tube orifice on paper, determining the number of staining tubes according to experimental requirements, resuspending cells with Buffer2 according to 100 μl/tube, adding surface antibody anti-sleep CD4/CD8, and incubating at 4deg.C in dark for 30min;
s805, washing: directly adding 2-4 ml/tube of Buffer2 solution, centrifuging at 1800rpm and 4deg.C for 8min;
s806, fixing; washing, removing the supernatant, gently swirling the cells, adding 4% paraformaldehyde 500-800 μl/tube, and incubating at room temperature in dark place for 8-10min;
s807, washing: adding Buffer3 solution 2-4 ml/tube, centrifuging at 1800rpm and 4deg.C for 8min;
s808, rupture of membranes: removing the supernatant, slightly swirling, adding 2-4 ml/tube of Buffer3 solution, and breaking membrane at 4 ℃ overnight;
s809, intracellular staining: after membrane rupture, collecting cells by centrifugation at 2200rpm and 4 ℃ for 8min, removing the supernatant, dipping a tube orifice on paper, gently swirling the cell sediment, re-suspending the cells to about 100 μl/tube with Buffer3 solution, respectively adding antibody IFN-gamma, gently swirling, and incubating at 4 ℃ for 30min in a dark place;
s8010, washing: adding 2-4 ml/tube of Buffer2 solution, centrifuging at 2200rpm and 4 deg.C for 8min;
s8011, on-machine detection: after removing the supernatant, gently vortexing, resuspending the cells to 300 μl/tube and performing on-machine detection to analyze CD4/CD8 + IFN-gamma expression in T cells, the dominant peptide was determined to stimulate PBMC to produce IFN-gamma.
The selected T cell dominant epitope peptide can stimulate the PBMC to produce the cytokine IFN-gamma in vitro. ID18 (rEg.P29) 86-100 ) With ID28 (rEg.P29) 136-150 ) After stimulation of PBMC, stimulation of CD4 was detected + T cells and CD8 + IFN-gamma production by T cells was found to be simultaneous stimulation of CD4 by ID18 + T and CD8 + IFN-gamma production in T cells, ID28 stimulates CD4 + IFN-. Gamma.production in T is shown in FIG. 11.
In fig. 11: A. detecting the IFN-gamma produced by flow cytometry; CD4/CD8 + T cells produce IFN-gamma statistics; * Representing P<0.05; * Represents P<0.01; * Represents P<0.0001。
Claims (1)
1. A echinococci granulosa recombinant antigen P29 dominant epitope peptide, characterized in that: the amino acid sequence of the dominant epitope peptide is as follows: QKNKEKITTTDKLGTALEQV, KLEEVRLDLDSDKTKLKNAKTAEQK, SVQLLDLIRAEKNYYEACAKECSMM, ALEQVASQSEKAAPQ or NFLNTTLSEAQKAKT.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211045917.4A CN115819542B (en) | 2022-08-30 | 2022-08-30 | Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211045917.4A CN115819542B (en) | 2022-08-30 | 2022-08-30 | Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115819542A CN115819542A (en) | 2023-03-21 |
| CN115819542B true CN115819542B (en) | 2023-11-28 |
Family
ID=85523263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211045917.4A Active CN115819542B (en) | 2022-08-30 | 2022-08-30 | Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115819542B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106046125A (en) * | 2016-06-30 | 2016-10-26 | 中国人民解放军第四军医大学 | CTL epitope peptide on HTNV GP as well as screening method and application thereof |
| CN108614121A (en) * | 2018-05-04 | 2018-10-02 | 山东师范大学 | Bovine viral diarrhea virus E2 proteantigen multi-epitope fusogenic peptides and its preparation and application |
| CN113577257A (en) * | 2021-07-28 | 2021-11-02 | 新疆医科大学第一附属医院 | Echinococcus granulosus EgTeg and EgFABP1 multi-epitope vaccine and application |
| CN113611362A (en) * | 2021-07-16 | 2021-11-05 | 广东药科大学 | Method for screening point mutation BIRC5 epitope peptide |
-
2022
- 2022-08-30 CN CN202211045917.4A patent/CN115819542B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106046125A (en) * | 2016-06-30 | 2016-10-26 | 中国人民解放军第四军医大学 | CTL epitope peptide on HTNV GP as well as screening method and application thereof |
| CN108614121A (en) * | 2018-05-04 | 2018-10-02 | 山东师范大学 | Bovine viral diarrhea virus E2 proteantigen multi-epitope fusogenic peptides and its preparation and application |
| CN113611362A (en) * | 2021-07-16 | 2021-11-05 | 广东药科大学 | Method for screening point mutation BIRC5 epitope peptide |
| CN113577257A (en) * | 2021-07-28 | 2021-11-02 | 新疆医科大学第一附属医院 | Echinococcus granulosus EgTeg and EgFABP1 multi-epitope vaccine and application |
Non-Patent Citations (1)
| Title |
|---|
| 朱明星等.细粒棘球蚴重组蛋白 P29 ( rEg. P29 ) 诱导下差异表达 mi c r oRNA 的筛选及分析. 中国病原生物学杂志.2021,第16卷(第9期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115819542A (en) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iborra et al. | Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis | |
| Read et al. | Transmission‐blocking antibodies against multiple, non‐variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement‐fixing | |
| Grotendorst et al. | A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies | |
| CN104519908A (en) | DNA vaccine for use in pancreatic cancer patients | |
| EP1881064A2 (en) | HCV-Anti-core monoclonal antibodies | |
| EP2480252A1 (en) | Methods, compositions, and kits for reducing anti-antibody responses | |
| VALO-HERRERA et al. | Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein | |
| CN108484758B (en) | anti-Ebola virus VP40 protein monoclonal antibody A2G7 and application thereof | |
| Pinitkiatisakul et al. | Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms | |
| CN110272488B (en) | Cat calicivirus monoclonal antibody and application thereof | |
| Zhou et al. | Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris | |
| CN105561343B (en) | A kind of DNA vaccination preventing human or animal's toxoplasmosis | |
| CN115819542B (en) | Screening and application of echinococci granulosa recombinant antigen P29 dominant epitope peptide | |
| Mo et al. | Protection of grouper against Cryptocaryon irritans by immunization with Tetrahymena thermophila and protective cross-reactive antigen identification | |
| CN103254312B (en) | Mouse monoclonal antibody and its preparation method and application thereof | |
| Vazini et al. | Evaluation of immune responses induced by GRA7 and ROP2 genes by DNA vaccine cocktails against acute toxoplasmosis in BALB/c mice | |
| CN107987159B (en) | Method for improving antibody titer in serum by immunizing animal with high-dose DNA immunization technology | |
| Nishikawa et al. | Delivery of Neospora caninum surface protein, NcSRS2 (Nc-p43), to mouse using recombinant vaccinia virus | |
| de Souza et al. | Production of a kinesin-related recombinant protein (Lbk39) from Leishmania braziliensis by Leishmania tarentolae promastigotes and its application in the serodiagnosis of leishmaniasis | |
| Gondim et al. | Characterization of an IgG monoclonal antibody targeted to both tissue cyst and sporocyst walls of Toxoplasma gondii | |
| CN104062430A (en) | Kit box used for detecting influenza virus in sample and detection method and application thereof | |
| CN108250293B (en) | anti-Ebola virus VP40 protein monoclonal antibody G7A6 and application thereof | |
| Drew et al. | Vaccination with plasmid DNA expressing antigen from genomic or cDNA gene forms induces equivalent humoral immune responses | |
| Constantinoiu et al. | Characterization of the antibody response in birds following infection with wild-type and attenuated strains of Eimeria tenella and Eimeria necatrix | |
| Ramos et al. | Production of monoclonal antibodies for immunoaffinity purification and quantitation of Blo t 1 allergen in mite and dust extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |